As of today (2022-08-11), Vertex Pharmaceuticals's share price is $296.74.
Vertex Pharmaceuticals's Owner Earnings per Share (TTM) ended in Jun. 2022 was $12.94. It's Price-to-Owner-Earnings for today is 22.93.
The historical rank and industry rank for Vertex Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:
VRTX'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.11 Med: 46.44 Max: 581.51
Current: 22.85
During the past 13 years, the highest Price-to-Owner-Earnings of Vertex Pharmaceuticals was 581.51. The lowest was 18.11. And the median was 46.44.
VRTX's Price-to-Owner-Earnings is ranked better than 64.33% of 171
companies
in the Biotechnology industry
Industry Median: 31.96
vs VRTX: 22.85
As of today (2022-08-11), Vertex Pharmaceuticals's share price is $296.74.
Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $12.37. Therefore, Vertex Pharmaceuticals's PE Ratio for today is 23.99.
As of today (2022-08-11), Vertex Pharmaceuticals's share price is $296.74.
Vertex Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $12.37. Therefore, Vertex Pharmaceuticals's PE Ratio without NRI for today is 23.99.
During the past 13 years, Vertex Pharmaceuticals's highestPE Ratio without NRI was 560.57. The lowest was 19.37. And the median was 29.67.
Vertex Pharmaceuticals Price-to-Owner-Earnings Historical Data
The historical data trend for Vertex Pharmaceuticals's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Vertex Pharmaceuticals Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Price-to-Owner-Earnings
286.54
53.47
44.48
21.21
27.44
Vertex Pharmaceuticals Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Price-to-Owner-Earnings
31.12
27.63
27.44
32.91
21.78
Competitive Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Price-to-Owner-Earnings Distribution
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Vertex Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals Price-to-Owner-Earnings Related Terms
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.97(0.33%) Volume: 325,121 10:40AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VRTX has been successfully added to your 
